These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24504686)

  • 1. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
    Sinha VP; Choi SL; Soon DK; Mace KF; Yeo KP; Lim ST; Howey DC
    J Clin Pharmacol; 2014 Jul; 54(7):792-9. PubMed ID: 24504686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.
    Sinha VP; Howey DC; Choi SL; Mace KF; Heise T
    Diabetes Obes Metab; 2014 Apr; 16(4):344-50. PubMed ID: 24118909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function.
    Linnebjerg H; Choi SL; Lam EC; Mace KF; Hodgson TS; Sinha VP
    Clin Pharmacol Drug Dev; 2016 May; 5(3):216-24. PubMed ID: 27163501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial.
    Morrow LA; Hompesch M; Jacober SJ; Leng Choi S; Qu Y; Sinha VP
    Diabetes Obes Metab; 2016 Nov; 18(11):1065-1071. PubMed ID: 27169522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.
    Henry RR; Mudaliar S; Ciaraldi TP; Armstrong DA; Burke P; Pettus J; Garhyan P; Choi SL; Jacober SJ; Knadler MP; Lam EC; Prince MJ; Bose N; Porksen N; Sinha VP; Linnebjerg H
    Diabetes Care; 2014 Sep; 37(9):2609-15. PubMed ID: 24947791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.
    Bergenstal RM; Rosenstock J; Bastyr EJ; Prince MJ; Qu Y; Jacober SJ
    Diabetes Care; 2014; 37(3):659-65. PubMed ID: 24198302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects.
    de la Peña A; Yeo KP; Linnebjerg H; Catton E; Reddy S; Brown-Augsburger P; Morrow L; Ignaut DA
    J Diabetes Sci Technol; 2015 Jul; 9(4):824-30. PubMed ID: 25697717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin.
    Manner DH; Luo J; Qu Y; Berry S; Gaydos BL; Jacober SJ
    Diabetes Technol Ther; 2014 Aug; 16(8):499-505. PubMed ID: 24825416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
    Pettis RJ; Ginsberg B; Hirsch L; Sutter D; Keith S; McVey E; Harvey NG; Hompesch M; Nosek L; Kapitza C; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):435-42. PubMed ID: 21355718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
    Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
    Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
    Kapitza C; Nowotny I; Lehmann A; Bergmann K; Rotthaeuser B; Nosek L; Becker RHA
    Diabetes Obes Metab; 2017 May; 19(5):622-627. PubMed ID: 27987252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.
    Bergenstal RM; Rosenstock J; Arakaki RF; Prince MJ; Qu Y; Sinha VP; Howey DC; Jacober SJ
    Diabetes Care; 2012 Nov; 35(11):2140-7. PubMed ID: 22787177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue.
    Caparrotta TM; Evans M
    Diabetes Obes Metab; 2014 May; 16(5):388-95. PubMed ID: 23941279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects.
    Becker RH; Frick AD; Teichert L; Nosek L; Heinemann L; Heise T; Rave K
    Diabetes Obes Metab; 2008 Nov; 10(11):1105-13. PubMed ID: 18355326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
    Heise T; Nosek L; Klein O; Coester H; Svendsen AL; Haahr H
    Diabetes Obes Metab; 2015 Jul; 17(7):659-64. PubMed ID: 25772444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability.
    Rave K; de la Peña A; Tibaldi FS; Zhang L; Silverman B; Hausmann M; Heinemann L; Muchmore DB
    Diabetes Care; 2007 Jul; 30(7):1777-82. PubMed ID: 17456839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.
    Ocheltree SM; Hompesch M; Wondmagegnehu ET; Morrow L; Win K; Jacober SJ
    Eur J Endocrinol; 2010 Aug; 163(2):217-23. PubMed ID: 20508081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.